SG Americas Securities
CRSP icon

SG Americas Securities’s CRISPR Therapeutics CRSP Stock Holding History

SG Americas Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Buy
28,185
+24,448
+654% +$1.29M ﹤0.01% 1635
2026
Q1 		$178K Sell
3,737
-10,097
-73% -$533K ﹤0.01% 2699
2025
Q4 		$725K Sell
13,834
-6,885
-33% -$412K ﹤0.01% 2276
2025
Q3 		$1.34M Sell
20,719
-17,763
-46% -$1.02M ﹤0.01% 1209
2025
Q2 		$1.87M Buy
38,482
+9,141
+31% +$354K 0.01% 806
2025
Q1 		$998K Buy
29,341
+8,240
+39% +$349K ﹤0.01% 1176
2024
Q4 		$831K Sell
21,101
-4,610
-18% -$218K ﹤0.01% 957
2024
Q3 		$1.21M Sell
25,711
-468
-2% -$23.7K ﹤0.01% 934
2024
Q2 		$1.41M Sell
26,179
-12,627
-33% -$730K 0.01% 1133
2024
Q1 		$2.65M Sell
38,806
-9,207
-19% -$659K 0.01% 771
2023
Q4 		$3.01M Buy
48,013
+24,850
+107% +$1.37M 0.03% 505
2023
Q3 		$1.05M Sell
23,163
-3,818
-14% -$197K 0.01% 1222
2023
Q2 		$1.51M Buy
26,981
+521
+2% +$29.6K 0.01% 865
2023
Q1 		$1.2M Sell
26,460
-873
-3% -$42.4K 0.01% 1022
2022
Q4 		$1.11M Buy
27,333
+14,493
+113% +$769K 0.01% 903
2022
Q3 		$839K Sell
12,840
-50,372
-80% -$3.65M 0.01% 1133
2022
Q2 		$3.84M Buy
63,212
+58,765
+1,321% +$3.45M 0.04% 392
2022
Q1 		$279K Sell
4,447
-18,703
-81% -$1.17M ﹤0.01% 2229
2021
Q4 		$1.75M Sell
23,150
-48,806
-68% -$4.26M 0.01% 1191
2021
Q3 		$8.05M Buy
71,956
+11,234
+19% +$1.41M 0.04% 342
2021
Q2 		$9.83M Buy
60,722
+1,012
+2% +$123K 0.05% 352
2021
Q1 		$7.28M Buy
59,710
+54,346
+1,013% +$8.21M 0.04% 380
2020
Q4 		$821K Sell
5,364
-1,543
-22% -$182K ﹤0.01% 1650
2020
Q3 		$578K Sell
6,907
-1,464
-17% -$130K ﹤0.01% 1538
2020
Q2 		$615K Buy
+8,371
New +$489K 0.01% 1892
2020
Q1 		– Sell
-6,585
Closed -$401K – 3478
2019
Q4 		$401K Sell
6,585
-11,919
-64% -$651K ﹤0.01% 1954
2019
Q3 		$758K Buy
+18,504
New +$884K 0.01% 1596

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SG Americas Securities's CRSP Position: Q2 2026 in Review

SG Americas Securities increased its CRISPR Therapeutics (CRSP) stake by 654% in Q2 2026, buying an estimated $1.29M and bringing the position to 28,185 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

SG Americas Securities first reported a position in CRSP in Q3 2019 and has held it in 27 quarters since. The position peaked at $9.83M in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • SG Americas Securities held 28,185 shares of CRISPR Therapeutics worth $1.54M as of Q2 2026.
  • SG Americas Securities bought 24,448 CRISPR Therapeutics shares in Q2 2026, an estimated $1.29M.
  • CRISPR Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1635 holding.
  • SG Americas Securities first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • SG Americas Securities's CRISPR Therapeutics position peaked at $9.83M in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.